An interventional study of The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in in Sarcopenia, sponsored by HSIAO MEI LAN. Completed at 1 site in Taiwan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by HSIAO MEI LAN · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Sarcopenia with a site in Taiwan — 30 open to participants now, 31 under way, none of them phase 3. Sarcopenia · Taiwan.
Among the 96 studies in Sarcopenia with a site in Taiwan, this one is the 43rd largest by enrollment of the 67 interventional ones that give a count, is one of 11 that started in 2025, is one of 63 with no phase, and was the 77th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →30 of the 96 studies in Sarcopenia with a site in Taiwan are open now. Recruiting first, the newest first:
Taipei Medical University Hospital · Sites in Taiwan
Ages 60+
Tzu Chi University · Sites in Taiwan
Ages 65–100 · Healthy volunteers
yueh chu wu · Sites in Taiwan
Ages 45–85
Valeria Chiu · Sites in Taiwan
Ages 18+ · Women only
National Health Research Institutes, Taiwan · Sites in Taiwan
Ages 40+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 11 started in 2025.
This study's enrollment of 60 is close to the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 80 across the 67 interventional studies, 151 across the 29 observational. Of the 51 that completed or were terminated, 4 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 96 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with HSIAO MEI LAN as lead sponsor.
HSIAO MEI LAN has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
7 of the studies in Sarcopenia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07830472Taipei Medical University HospitalLower-Limb Rehabilitation Robot Training for Sarcopenia | 2026-12 |
| NCT02635022National Taiwan University HospitalFragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study | 2026-12 |
| NCT07815158National Yang Ming Chiao Tung UniversityMulti-Component Nutrition, Intrinsic Capacity, and Physical Function in Older Adults | 2026-12-15 |
| NCT07726758Tzu Chi UniversityThe Effectiveness of Squat Exercise for Improving Pre-Sarcopenia in Order Adults | 2026-12-31 |
| NCT07465393Valeria ChiuFacility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 96 studies in Sarcopenia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. This randomized controlled trial (RCT) will evaluate a 12-week smart-technology-based program for 60 older adults at risk of sarcopenia.
Intervention:
Participants in the intervention group will receive a technology-assisted program delivered through a Line Bot system. The platform provides personalized exercise training videos, nutrition education, daily reminders, and a point-based logging system to support adherence and monitor engagement. The control group will receive standard clinic-based care.
Purpose:
The study aims to examine whether the smart technology intervention can improve muscle mass, physical performance, quality of life, and self-management ability among older adults at risk of sarcopenia.
Expected Benefit:
The digital intervention is anticipated to offer a more effective, accessible, and sustainable approach compared with standard care, providing practical support for preventing muscle decline in community-dwelling older adults
This randomized controlled trial (RCT) is designed as a 12-week intervention to evaluate the efficacy of a smart technology-assisted nutrition and exercise program for community-dwelling older adults (aged ≥ 65 years) at risk of sarcopenia. Participants (N = 60) will be randomly assigned to either the intervention group (n = 30) or the control group (n = 30). Data will be collected at baseline, week 8 (mid-intervention), and week 12 (post-intervention).
Intervention Group:
Participants will receive the 12-week program delivered through a dedicated Line Bot platform. Core components include:
Exercise Training: Three progressive exercise videos (resistance, aerobic, and balance training) designed to enhance muscle function.
Nutrition Education: One video focusing on adequate protein intake and dietary habits essential for muscle maintenance.
Smart Technology Features: The Line Bot functions as a personalized case management tool, offering daily reminders for exercise and protein intake, an interactive calculator for estimating daily protein consumption, and a digital logging system with motivational rewards to support adherence and self-management behaviors.
Control Group:
Participants will receive standard outpatient care and general health education pamphlets. They will not receive access to the Line Bot system, exercise videos, or personalized support.
Primary outcome data will be collected at week 12. Statistical analyses will include descriptive statistics and inferential methods, such as repeated measures analysis of variance (ANOVA), to examine the effectiveness of the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Score ≥ 11 on the SARC-CalF questionnaire, indicating risk of sarcopenia.
No evident functional impairment in the limbs and able to complete handgrip strength, walking speed, and muscle mass assessments.
Possesses basic reading, writing, and calculation abilities sufficient to understand study-related materials and complete and daily logs.
Owns a smartphone and has used it for at least one year, with basic operational ability (e.g., sending and receiving LINE messages, scanning QR codes).
Exclusion Criteria
Self-reported functional impairment in any limb.
Requires assistance from a wheelchair, walker, or cane for ambulation.
Has an implanted cardiac pacemaker.
Currently participating in, or planning to participate in, other physical training courses or nutrition programs during the study period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention group (n=30) will receive a 12-week smart technology-assisted combined exercise and nutrition program. The intervention is delivered via a dedicated Line Bot platform, which provides: 1) Three progressive exercise training videos (resistance, aerobic, and balance) , \*\*with the goal of participants completing five exercise sessions per week using the provided materials\*\*. 2) Nutrition education videos focusing on protein intake. 3) Interactive features including daily reminders, protein intake calculation tools, and a digital diary with motivational elements to promote adherence and self-management.
Behavioral: The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in
Participants in the control group (n=30) will receive standard outpatient care for sarcopenia risk management, which includes general health education pamphlets and regular follow-ups at the clinic. They will not receive any specialized exercise training, nutrition videos, or access to the Line Bot platform during the 12-week intervention period.
The 12-week progressive exercise program (resistance, aerobic, and balance training) is uniquely delivered and monitored via a dedicated \*\*Line Bot platform\*\*. This differentiates it from traditional in-person or non-interactive video programs. The platform includes interactive features like daily reminders and a digital diary to enhance adherence and support participant self-management, aiming for five exercise sessions per week.
Appendicular Skeletal Muscle Mass (ASM) by Bioelectrical Impedance Analysis (BIA)
The change in skeletal muscle mass will be assessed using Appendicular Skeletal Muscle Mass (ASM), derived from bioelectrical impedance analysis (BIA). The primary endpoint is the between-group difference in the absolute change in ASM (in kilograms) from baseline to the end of the 12-week intervention (Week 12)
Time frame: Baseline (Week 0), Week 8, and Final Assessment at Week 12.
Plan to share: No — IPD will not be shared due to the lack of dedicated infrastructure and resources for data hosting, curation, and the formal management of external data access requests in this small, investigator-initiated study.
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Aug 2026, 8 months.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 8 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2028 → Aug 2026 and completion Dec 2028 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.